Evidence map›Paper›PMID 39959029›Full record

ArticleCanadian journal of gastroenterology & hepatology2025

Therapeutic Drug Monitoring for Dose Optimization of Infliximab in Patients With Inflammatory Bowel Disease: An Analysis of Canadian Real-World Data.

David C Sealey, Kai Fai Ho, Z Christina Zhou, Michael Clark, Brian G Feagan, Remo Panaccione, A Hillary Steinhart, Elena Bolshtyansky, Martin Williamson, Waqqas Afif

Abstract read
In one paragraph

Article in Canadian journal of gastroenterology & hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. A review to determine regulatorily and reimbursement successes of studies conducted using data from Canadian patient support programs based on the real-world evidence guidelines published by Canadian drug agency and health Canada.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David C SealeyJohnson & Johnson, Toronto, Ontario, Canada.ORCID 0000-0001-7764-9527
Kai Fai HoSTAT-TU Inc., Elora, Ontario, Canada.
Z Christina ZhouJohnson & Johnson, Toronto, Ontario, Canada.ORCID 0009-0003-9511-1175
Michael ClarkJohnson & Johnson, New Brunswick, New Jersey, USA.ORCID 0000-0003-4949-1608
Brian G FeaganDepartments of Medicine and Epidemiology and Biostatistics, Western University, London, Ontario, Canada.ORCID 0000-0002-6914-3822
Remo PanaccioneDivision of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0002-5247-940X
A Hillary SteinhartZane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada.ORCID 0009-0000-4781-9601
Elena BolshtyanskyJohnson & Johnson, New Brunswick, New Jersey, USA.
Martin WilliamsonJohnson & Johnson, Toronto, Ontario, Canada.ORCID 0000-0001-9434-6712
Waqqas AfifDivision of Gastroenterology, McGill University Health Center, Montreal, Québec, Canada.ORCID 0000-0001-6869-0982

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gastrointestinal AgentsInflammatory Bowel DiseasesInfliximabAdolescentAdultAgedAged, 80 and overCanadaColitis, UlcerativeCrohn DiseaseDrug MonitoringFemaleHumansMaleMiddle AgedRetrospective StudiesGastrointestinal AgentsInfliximabCrohn's diseaseinflammatory bowel diseaseinfliximabpatient support programreal-world evidencetherapeutic drug monitoringulcerative colitis

Identifiers

PMID39959029
PMCPMC11825194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.